| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 16, 2024 4:01 P.M. |
| Form: | S-1 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 16, 2024 4:01 P.M. |
| Form: | S-1 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/17/2025 | $50.00 | Buy | Craig Hallum |
| 5/16/2025 | $24.00 | Outperform → Neutral | Robert W. Baird |
| 6/27/2024 | $65.00 | Outperform | BMO Capital Markets |
| 6/11/2024 | $54.00 | Outperform | Robert W. Baird |
| 4/29/2024 | $46.00 | Outperform | Leerink Partners |
| 3/21/2024 | $61.00 | Outperform | William Blair |
Craig Hallum initiated coverage of Neurogene with a rating of Buy and set a new price target of $50.00
Robert W. Baird downgraded Neurogene from Outperform to Neutral and set a new price target of $24.00
BMO Capital Markets initiated coverage of Neurogene with a rating of Outperform and set a new price target of $65.00
Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences: Guggenheim Emerging Outlook: Biotech Summit 2026 Format: Management will participate in a fireside chat and investor meetings Date: Thursday, February 12 at 9:00 a.m. ET TD Cowen 46th Annual Health Care Conference Format: Management will participate in a fireside chat and investor meetings Date: Wednesday, March 4 at 10:30 a.m. ET Leerink Global Healthcare Conference Format: Management will participate in a fireside chat and investor
Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 2,820 shares of the Company's common stock to one new employee (the "Inducement Grant") on February 2, 2026 (the "Grant Date"). The Inducement Grant has been granted pursuant to the Company's 2025 Inducement Plan. The Inducement Grant was granted as an inducement material to this individual entering into employment with Neurogene in accordance with Nasdaq Listing Ru
Dosed multiple participants in Embolden™ registrational trial in fourth quarter of 2025 Completion of dosing in Embolden expected in second quarter of 2026 Plan to present interim data on pediatric and adolescent/adult cohorts from Phase 1/2 trial in mid-2026 Early commercial-readiness activities underway Neurogene to present at J.P. Morgan Healthcare Conference on January 14 at 7:30 a.m. PT Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today provided an update on recent achievements for NGN-401 gene therapy for the treatment of Rett syndrome and plans for mul
4 - Neurogene Inc. (0001404644) (Issuer)
4 - Neurogene Inc. (0001404644) (Issuer)
4 - Neurogene Inc. (0001404644) (Issuer)
4 - Neurogene Inc. (0001404644) (Issuer)
4 - Neurogene Inc. (0001404644) (Issuer)
4 - Neurogene Inc. (0001404644) (Issuer)
8-K - Neurogene Inc. (0001404644) (Filer)
8-K - Neurogene Inc. (0001404644) (Filer)
10-Q - Neurogene Inc. (0001404644) (Filer)
Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an update on its ongoing Phase 1/2 open-label clinical trial evaluating NGN-401 gene therapy for the treatment of Rett syndrome. As previously disclosed, on November 11, 2024, Neurogene became aware of an emerging treatment-related serious adverse event (SAE) in a trial participant who received NGN-401 at a dose of 3E15 vg (high-dose cohort). This participant, who was dosed on November 5, subsequently experienced signs of a systemic hyperinflammatory syndrome, a rare and life-threatening immune response tha
Expanded Phase 1/2 gene therapy trial for Rett syndrome to inform future registrational study design; Company remains on track to share interim clinical data in 4Q:24 Strong financial position with runway into 2H:26 following reverse merger and private financing in December 2023 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2023 financial results and highlighted recent corporate updates. "We started the year with strong execution in our Phase 1/2 NGN-401 gene therapy trial for female pediatric patients with Rett syndrom
All participants experienced a 2-point improvement in the clinician-rated Clinical Global Impression-Improvement (CGI-I) scale from baseline All participants improved in the caregiver-completed Rett Syndrome Behavior Questionnaire (RSBQ), ranging from 28 to 52 percent improvement from baseline All participants with disruptions in sleep, constipation, and dysphagia at baseline demonstrated objective improvements Gains in skill and developmental milestones were consistent, durable, deepened over time and demonstrated improvements not expected based on natural history data Low-dose NGN-401 well-tolerated with favorable safety profile Company plans to provide an update of registration
Company to host webcast to review data on November 11 at 4:30 p.m. ET Late-breaker poster to be presented during Child Neurology Society Meeting on November 12 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it will host a webcast to present interim efficacy data from the low-dose cohort of its ongoing Phase 1/2 clinical trial of NGN-401 gene therapy for pediatric patients with Rett syndrome on November 11, 2024 at 4:30 p.m. ET. Safety data from the low- and high-dose cohorts will also be shared. These data will also be presented in a late-breaking
SC 13G - Neurogene Inc. (0001404644) (Subject)
SC 13G/A - Neurogene Inc. (0001404644) (Subject)
SC 13G/A - Neurogene Inc. (0001404644) (Subject)